Skip to main content
OpenTrials
Completed

NCT Number: NCT02448758

Cohort of Non-small Cell Lung Cancer With Mutation of the Nord Pas de Calais (CB(NPC)²)

The investigators propose to create a database at the regional level, the principle is to include all patients in whom a mutation was detected from a single platform (Lille). The creation of this regional cohort, smaller than the national cohort of Biomarkers France, will perform a more comprehensive collection of clinical data, and molecular monitoring data of patients included. To increase the completeness of the collection of information, it will not be based on voluntary prescribing clinician but will be largely carried out by CRA dedicated to this activity.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Non-small Cell Lung Cancer Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHRU, Lille, France

Loading trial locations.

About this study

This is a prospective and retrospective study of a population of patients with mutated non-small cell lung cancer in the Nord Pas de Calais. Retrospective cohort will involve patients with main molecular abnormalities, identifiable from molecular biology platform CRRC, except EGFR and KRAS treated from September 2011 to February 2013.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged ≥ 18 years old
  • Patient with non-small cell lung cancer
  • Detected in the Nord Pas de Calais
  • Monitored in the Nord Pas de Calais
  • Patient must have signed a non-opposition form to the use of medical data

Exclusion criteria

  • No identified mutation

Treatment and study plan

Primary outcomes

  1. Correlation between clinical factors and mutation status

    Time frame: at baseline

    The clinical factors are age, smoking status, occupational and environmental exposure, personal and family background, TNM stage, performance status

Secondary outcomes

  1. Progression-free survival

    Time frame: 3 years

  2. Overall survival

    Time frame: 3 years

  3. Number of patients included in a clinical trial dedicated to a certain type of non-small cell lung cancer with mutation

    Time frame: 3 years

  4. Number of cases per mutation type

    Time frame: 3 years

Sponsors and collaborators

Lead sponsor

Centre Oscar Lambret

Other

Collaborators

  • Centre de Biologie Pathologie : Plateforme de Biologie Moléculaire de Lille
  • University Hospital, Lille

Registry information

Official study title

Cohort of Non-small Cell Lung Cancer With Mutation of the Nord Pas de Calais

Acronym: CB(NPC)²

Important dates

Study start
2013
Primary completion
2016
Study completion
2017
First posted
May 19, 2015
Registry last updated
Mar 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.